Methylation testing for cervical cancer is of great significance in the diagnosis and treatment of cervical cancer, and can play a role in cervical cancer screening and triage, as well as treatment follow-up of cervical lesions. At present, more than 100 kinds of methylation markers can be detected in cervical tissues, and there is a close relationship between the methylation expression status of genes and cervical lesions. Methylation testing can play a role in cervical cancer screening and triage, cervical lesion treatment and follow-up, judging the progression of cervical lesions, and predicting the prognosis of cervical cancer. 1. The role of cervical cancer screening triage: by triaging cytological abnormalities and HPV-positive women through methylation testing, the detection of patients with high-grade cervical lesions can be improved, thus reducing unnecessary colposcopic referrals, and methylation testing can play a very good role in cervical cancer screening triage. 2. The role of cervical lesion treatment follow-up: after receiving treatment for high-grade cervical lesions, the recurrence is high, and it is necessary to review the cytology or HPV test at 6, 12 and 24 months. Methylation can be used as a monitoring index after the treatment of high-grade cervical lesions, and when the patients are methylation-positive, the probability of recurrence is greater than that of patients with negative test results. 3. Role in determining the progression of cervical lesions: by monitoring the methylation status of different genes, it is possible to predict whether there is any risk, and whether there is any tendency to change to high risk. 4. Predicting the prognosis of cervical cancer: Methylation monitoring can also be used as a prognostic indicator for cervical cancer, and some gene promoter methylation is associated with the recurrence of cervical cancer.